About Company’s Business:
They offer digital-led commercialization services tailored for the life sciences sector, encompassing biopharmaceutical, emerging biotech, and medical device firms. These services support various stages, from drug development and clinical trials to regulatory submissions, pharmacovigilance, complaints management, and sales and marketing endeavors. Leveraging over two decades of healthcare expertise and technology platforms, they deliver solutions aiding in clinical trials, regulatory compliance, product launches, and ongoing sales and marketing efforts. Their comprehensive portfolio addresses commercial, medical, regulatory, and R&D facets of life sciences companies. By December 31, 2023, they served 65 active clients through six operational hubs and 17 offices spanning North America, Europe, and Asia.
About the Industry:
The life sciences sector, dominated by biopharmaceutical and medical device firms, saw combined sales of â‚ą138.3 trillion (US$1.8 trillion) in 2023, with biopharmaceuticals contributing 69% at â‚ą95.4 trillion (US$1.2 trillion). Sales are projected to reach â‚ą163.5 trillion (US$2.1 trillion) by 2026 due to factors like aging populations and increased chronic diseases. Operational expenses, including marketing, clinical trials, and regulatory affairs, were â‚ą12.0 trillion (US$156 billion) in 2022, forecasted to grow to â‚ą15.5 trillion (US$201 billion) by 2026
Key Financial Information (â‚ą in million):
| Particulars | Dec 31, 2023 | Dec 31, 2022 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 |
|---|---|---|---|---|---|
| (A) Equity share capital | 443.51 | 442.45 | 442.95 | 3.51 | 3.13 |
| (B) Net Worth(1) | 13,270.01 | 10,114.87 | 10,637.22 | 7,639.00 | 3,245.13 |
| (C) Total Income(2) | 19,697.49 | 17,187.58 | 23,640.98 | 16,904.97 | 9,969.20 |
| (D) Restated profit from continuing operations after tax | 2,419.02 | 2,172.79 | 2,660.99 | 1,628.18 | 1,856.82 |
| (E) Return on Net Worth (%) | 18.23% | 21.48% | 25.02% | 21.57% | 46.04% |
| (F) Earnings per equity-share - continuing operations | |||||
| Basic- | 10.91 | 9.83 | 12.03 | 7.50 | 9.40 |
| Diluted- | 10.84 | 9.79 | 11.97 | 7.46 | 8.74 |
| (G) Net Asset Value per | |||||
| Equity Share (in â‚ą)(7) | 59.86 | 45.75 | 48.10 | 34.80 | 16.42 |
| (H) Total borrowings(8) | 3,993.33 | 4,110.74 | 3,943.36 | 182.38 | 247.64 |
Objective of the Issue:
-
Repayment/prepayment of indebtedness of one of our Material Subsidiaries, ILSL Holdings.
-
Funding the capital expenditure requirements of our Company and one of our Material
Subsidiaries, Indegene, Inc -
General corporate purposes.
For more detailed information, you can refer to the IPO Prospectus (RHP) filed by the company.
| Important information regarding the IPO | |
|---|---|
| Open Date | Monday, May 6, 2024 |
| Close Date | Wednesday, May 8, 2024 |
| Issue Size | â‚ą1,841.76 Crores |
| Price | â‚ą430 to â‚ą452 per share |
| Lot Size | 33 Shares |
| Basis of Allotment | Thursday, May 9, 2024 |
| Initiation of Refunds | Friday, May 10, 2024 |
| Credit of Shares to Demat | Friday, May 10, 2024 |
| Listing Date | Monday, May 13, 2024 |
How to apply for this IPO?
You can locate the redirection link to the IPO on the home screen of the Dhan App. Alternatively, you can access it by navigating to the “Money” Section at the bottom right and swiping right to reach the “IPO” Tab.
Do let us know your thoughts on this IPO.